Role of 5 Alpha-Reductase Inhibitors in the Management of Prostate Cancer

    December 2006 in “ Clinical interventions in aging ”
    Steven J. Hudak, Javier Hernández, Ian M. Thompson
    Studysummary This analysis of the Prostate Cancer Prevention Trial found that finasteride reduces prostate cancer risk by nearly 25% and enhances the PSA test's ability to detect prostate cancer and high-risk diseases.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on europepmc.org →
    Discuss this study in the Community →

    Research cited in this study 6

    1. Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period The Journal of Urology · 2006
    2. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia The New England Journal of Medicine · 2003
    3. The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia The New England Journal of Medicine · 1998
    4. Clinical Pharmacokinetics and Pharmacodynamics of Finasteride Clinical Pharmacokinectics · 1996
    5. The Effect of Finasteride in Men with Benign Prostatic Hyperplasia The New England Journal of Medicine · 1992
    6. The Clinical Development of a 5α-Reductase Inhibitor, Finasteride The Journal of Steroid Biochemistry and Molecular Biology · 1990